Developing a new treatment for bronchopulmonary dysplasia in infants
Development of a systems pharmacology agent for treatment of bronchopulmonary dysplasia
This study is working on a new medicine to help treat bronchopulmonary dysplasia (BPD) in premature babies, and the researchers are making sure it’s safe to test in humans so that it can eventually be available to those who need it.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Reneurogen, LLC NIH-funded |
| Lab location | 1 site (Elm Grove, United States) |
| Project ID | NIH-11311467 on NIH RePORTER |
What this research studies
This research focuses on creating a novel drug candidate aimed at treating bronchopulmonary dysplasia (BPD), a serious lung condition affecting premature infants. The drug, known as N-acetyl-lysyltyrosylcysteine amide (KYC), has shown promising results in animal models. The research team is working on regulatory planning and engaging with the FDA to ensure the drug can be safely tested in humans. By collaborating with experts in pediatric drug development, the team aims to navigate the complexities of bringing this treatment to market.
Who could benefit from this research
Good fit: Ideal candidates for this research are premature infants diagnosed with bronchopulmonary dysplasia.
Not a fit: Patients who are not premature or do not have bronchopulmonary dysplasia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new effective treatment for infants suffering from bronchopulmonary dysplasia, improving their lung health and overall quality of life.
How similar studies have performed: Previous research has shown success with similar pharmacological approaches in treating chronic lung diseases in infants, indicating potential for this novel treatment.
Where this research is happening
Elm Grove, United States
- Reneurogen, LLC — Elm Grove, United States (Active)
Researchers
- Principal investigator: Naylor, Stephen — Reneurogen, LLC
- Study coordinator: Naylor, Stephen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.